<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, clinical manifestations and diagnosis of hepatitis D virus infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, clinical manifestations and diagnosis of hepatitis D virus infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, clinical manifestations and diagnosis of hepatitis D virus infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francesco Negro, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna SF Lok, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rafael Esteban, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis D virus (HDV) infection is caused by a defective virus: the hepatitis D virus. HDV is often referred to as hepatitis delta virus or delta agent. However, the term HDV is preferred. Individuals with hepatitis D are always dually infected with HDV and hepatitis B virus (HBV). Although HDV can replicate autonomously, the simultaneous presence of HBV is required for complete virion assembly and secretion.
        </p>
        <p>
         This topic review will provide general information concerning the virology, epidemiology, clinical features, and diagnosis of HDV infection. Issues related to treatment, prevention, and liver transplantation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3664.html" rel="external">
          "Treatment and prevention of hepatitis D virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4582.html" rel="external">
          "Liver transplantation in adults: Hepatitis D virus reinfection in liver transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          VIROLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3464135574">
         <span class="h2">
          HDV virion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hepatitis D virion comprises an RNA genome, a single HDV encoded antigen, and a lipoprotein envelope provided by hepatitis B virus (HBV) (
         <a class="graphic graphic_figure graphicRef63575" href="/z/d/graphic/63575.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HDV genome
         </strong>
         – The HDV genome is a small RNA molecule (1676 to 1683 nucleotides in size) bearing some structural analogies with plant viroids and virusoids [
         <a href="#rid1">
          1
         </a>
         ]. HDV RNA is a single-stranded circle, with a high degree of self-complementarity and G+C content causing the circle to collapse as a rod-like structure [
         <a href="#rid1">
          1
         </a>
         ]. Significant sequence heterogeneity (as high as 40 percent) exists among the different HDV isolates that have been sequenced, and a classification into eight HDV genotypes has been proposed [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatitis D antigen
         </strong>
         – The only antigen associated with HDV, the hepatitis D antigen (HDAg), is a structural component of the virion. It consists of a protein encoded by an open reading frame present on the RNA strand complementary to the RNA genome (antigenomic strand) [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 70 molecules of HDAg are complexed with each molecule of HDV RNA to form the viral ribonucleoprotein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two forms of HDAg are co-expressed in infected individuals. Each HDAg has a different function as described below. (See
         <a class="local">
          'Pathogenesis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The two HDAg molecules differ by 19 amino acids at the C-terminus; the molecular weights are approximately 24 and 27 kilodaltons (kd). Their synthesis arises via an RNA editing process during HDV replication [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The stop codon UAG of the messenger RNA directing the synthesis of the HDAg causes the translation of HDAg to terminate, thereby giving rise to the small HDAg. During HDV RNA replication, this stop codon is deaminated on the antigenomic HDV RNA by a cellular enzyme (the adenosine deaminase acting on RNA 1, ADAR1) to UIC (in which "I" stands for inosine).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During the next replication cycle, the "I" on the antigenomic RNA is read as a "G," leading to the replacement of the "A" with a "C" in the genomic HDV RNA. During the transcription of the messenger RNA directing the synthesis of the HDAg, the "C" will lead to the replacement of the UAG stop codon with a UGG codon, which directs the incorporation of tryptophan into the nascent HDAg. Translation of HDAg then proceeds until a new stop codon is reached, 19 amino acids downstream, thereby giving rise to the large HDAg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lipoprotein envelope of HDV
         </strong>
         – The lipoprotein envelope of HDV is provided by the HBV and consists of the same proteins (large, middle, and small S) that are found in the HB virion; their relative proportion depends upon the level of HBV replication [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2889596962">
         <span class="h2">
          HDV life cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with hepatitis D are always dually infected with HDV and HBV. Although HDV can replicate autonomously [
         <a href="#rid1">
          1
         </a>
         ], the simultaneous presence of HBV is typically required for complete virion assembly and secretion. Due to interference mechanisms that are not well understood, HBV replication is suppressed in most HDV-infected individuals.
        </p>
        <p>
         HDV replicates at very high levels in hepatocytes [
         <a href="#rid5">
          5
         </a>
         ]. The sodium taurocholate cotransporting polypeptide (NTCP), which is the receptor for HBV, has also been identified as the receptor for HDV [
         <a href="#rid6">
          6,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3631.html" rel="external">
          "Characteristics of the hepatitis B virus and pathogenesis of infection", section on 'Replication cycle'
         </a>
         .)
        </p>
        <p>
         The steps in the HDV replication cycle can be summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once inside the hepatocyte, HDV RNA is found within the nucleus, where it is transcribed into its complementary RNA (antigenomic HDV RNA). Two forms of antigenomic HDV RNA exist: a 0.8 kilobase (kb) RNA, which is the messenger RNA being translated into the HDAg [
         <a href="#rid8">
          8
         </a>
         ], and the full-length 1.7 kb RNA, which is the template directing the transcription back into the HDV genome [
         <a href="#rid1">
          1
         </a>
         ]. The host RNA polymerase II appears to be involved in the transcription of the 0.8 kb mRNA in a process that is regulated by direct binding with the HDAg itself [
         <a href="#rid9">
          9,10
         </a>
         ]. In addition, the transcription of the full-length genomic and antigenomic RNAs occurs by the cellular RNA polymerase II [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDV RNA replication is
         <strong>
          activated
         </strong>
         by the small HDAg through direct binding of the HDAg to the HDV RNA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The large HDAg
         <strong>
          suppresses
         </strong>
         HDV replication. In addition, it directs packaging of the HD virion through an interaction between the extra 19 amino acids at the C-terminal end and the small S protein (surface antigen of the hepatitis B virus [HBsAg]) of the helper HBV [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Completion of the HD virion assembly and release is dependent on the simultaneous presence of HBV which provides the envelope. Without HBV, HDV cannot be rescued and exit the cells.
        </p>
        <p>
        </p>
        <p>
         There have been some case reports of HDV infection occurring in the absence of hepatitis B coinfection in patients with hepatitis C virus (HCV) infection and Sjögren's disease [
         <a href="#rid12">
          12,13
         </a>
         ]. However, these findings have not been confirmed in subsequent studies [
         <a href="#rid14">
          14-16
         </a>
         ]. As an example, one study of 2123 plasma samples positive for anti-HCV antibody found that 1.9 percent of samples tested positive for HDV antibody (anti-HDV) but none were HDV RNA positive, suggesting that HCV may not have a supportive role in HDV transmission [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         However, divergent HDV-like viruses have been detected in fish, birds, amphibians, and invertebrates, without evidence of any HBV-like agent supporting infection [
         <a href="#rid17">
          17
         </a>
         ]. Another study found that HDV can be transmitted and propagated in experimental infections ex vivo and in vivo by different enveloped viruses unrelated to HBV, including HCV and flaviviruses such as Dengue and West Nile virus [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1828477952">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The detailed mechanisms by which HDV induces liver damage are unknown. However, the pathogenesis of hepatitis D-related liver disease appears to depend on the interplay of three major factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDV-associated factors, such as genotype [
         <a href="#rid19">
          19
         </a>
         ] and the expression of specific HDV antigen (HDAg) species [
         <a href="#rid20">
          20
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Host-associated factors, such as the immune response
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Helper virus-associated factors, such as the hepatitis B virus (HBV) genotype and the level of HBV replication [
         <a href="#rid21">
          21
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         HDV is believed to cause direct cytopathic damage during acute infection, whereas immune-mediated damage predominates during chronic infection [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2955894702">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on HDV epidemiology have mostly been gathered in chronic hepatitis B virus (HBV) carriers superinfected with HDV, in whom HDV infection has progressed to chronicity. HDV antibody (anti-HDV) is present in high titers in these patients, and the prevalence of chronic HDV infection can be reliably determined.
        </p>
        <p>
         However, the incidence of acute hepatitis D may be underestimated [
         <a href="#rid22">
          22
         </a>
         ]. Although the commercial availability of assays for the detection of anti-HDV has improved our understanding of the epidemiology of HDV infection, these assays have limitations. As an example, in acute hepatitis D, anti-HDV appears very late and may be missed if repeated testing is not performed. This is especially true in immunocompromised individuals (eg, patients with human immunodeficiency virus [HIV]) in whom a strong antibody response to HDV may be delayed or absent. Furthermore, after resolution of acute hepatitis D, anti-HDV may disappear with time. Thus, in some patients, recognition of past HDV infection may be impossible. More detailed discussion of diagnostic testing is presented below. (See
         <a class="local">
          'Diagnosis of HDV infection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H273602861">
         <span class="h2">
          Prevalence of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of HDV in patients with chronic HBV infection varies across studies. These variations are likely due to several factors, including lack of high-quality data because of under-testing of HDV in persons with chronic HBV infection, the variable accuracy of HDV screening tests, and the lack of population-based studies (much of the available data focuses on patients who are at high risk for HDV infection or who have more advanced liver disease).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence worldwide
         </strong>
         – Historical data suggest that approximately 15 to 20 million of the 257 million HBV carriers worldwide may be infected with HDV [
         <a href="#rid23">
          23,24
         </a>
         ]. Data from meta-analyses and systematic reviews on the global burden of chronic HDV infection vary widely, with an estimated number of persons infected ranging from 12 million to 72 million [
         <a href="#rid25">
          25-27
         </a>
         ]. The 2017 World Health Organization (WHO) Global Hepatitis Report estimated that 5 percent of individuals with HBV infection are coinfected with HDV (ie, approximately 15 million individuals infected with HDV worldwide) [
         <a href="#rid28">
          28
         </a>
         ]. In another report, the HDV prevalence was estimated at 25.8 and 19.8 percent in HBV patients with cirrhosis or hepatocellular carcinoma, respectively [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence in the United States
         </strong>
         – In the United States, the prevalence of HDV infection also varies and reports range from 6 to 42 percent of persons with chronic HBV [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study of hepatitis B surface antigen (HBsAg)-positive adults in the 2011 to 2016 National Health and Nutrition Examination Survey (NHANES) 42 percent were anti-HDV positive (33 percent among United States born and 46 percent among foreign born) [
         <a href="#rid29">
          29
         </a>
         ]. However, this nationwide prevalence estimate was extrapolated from a total of 113 HBsAg-positive persons who may not be representative of the general population, and there were concerns about false positive results with the assay that was used. By contrast, a different report found that only 6 percent of persons with chronic HBV infection screened for anti-HDV in one United States hospital tested positive between 2016 to 2021 [
         <a href="#rid30">
          30
         </a>
         ]. One report estimated that 14 percent of foreign-born Americans with chronic HBV had HDV infection using 2019 US census bureau data and data on HDV prevalence from the countries these persons emigrated from (although data were missing or inadequate in many countries) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In some countries, such as Italy, improvements in socioeconomic conditions, increased awareness of how infectious diseases are transmitted, and aggressive vaccination campaigns against HBV led to a dramatic decrease in the incidence of HBV infection and the spread of HDV infection among young adults through 1999 [
         <a href="#rid32">
          32
         </a>
         ]. However, this decline appears to have stopped, and some recrudescence of HDV prevalence has been reported in both the Mediterranean area [
         <a href="#rid33">
          33
         </a>
         ] and in Central Europe [
         <a href="#rid34">
          34
         </a>
         ]. Immigration from endemic countries has been suggested to be the cause for this trend [
         <a href="#rid35">
          35,36
         </a>
         ], but is not the only reason: injection drug use, sexual practices, and body modification procedures may also be involved. (See
         <a class="local">
          'Risk factors for disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1720627216">
         <span class="h2">
          Risk factors for disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDV is predominantly confined to groups with known risk factors for HDV (persons who inject drugs, individuals who have received multiple transfusions in the past, men who have sex with men who engage in unsafe sexual behaviors [eg, condomless sex with multiple partners], and persons who emigrated from countries with a high prevalence of HDV infection). (See
         <a class="local">
          'Geographic distribution'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H176159701">
         <span class="h2">
          Geographic distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDV is not distributed uniformly across the globe, and the geographic distribution of HDV infection does not parallel that of HBV. As an example, there is a high prevalence in the Mediterranean Basin, Mongolia, Moldova, and some countries in Sub-Saharan Africa [
         <a href="#rid27">
          27
         </a>
         ], whereas other areas, including many Asian countries, are relatively spared despite the high prevalence of HBV infection. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Mediterranean Basin
         </strong>
         – HDV infection is endemic in the Mediterranean Basin, where intrafamilial spread is thought to have been prominent in the past, but data suggest that the prevalence of HDV infection has declined. In a study from Italy, anti-HDV antibodies were detected in only 69 of 834 HBsAg-positive patients (8.3 percent) in 1997, compared with 23 and 14 percent in studies from 1987 and 1992, respectively [
         <a href="#rid32">
          32
         </a>
         ]. The decrease resulted principally from a reduction in chronic HDV infection in young adults. In addition, vaccination campaigns against HBV have decreased HDV infection as well. However, more recent data suggest the prevalence appears to be increasing in immigrant populations [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asia
         </strong>
         – The prevalence of HDV infection among HBV carriers in Asia is quite variable. Although low in Japan [
         <a href="#rid22">
          22
         </a>
         ], other countries, especially Mongolia and those in Central Asia, are heavily affected, and the prevalence among HBV carriers can be as high as 60 percent in some areas in Pakistan [
         <a href="#rid39">
          39
         </a>
         ]. HDV infection is not infrequent in Taiwan [
         <a href="#rid40">
          40
         </a>
         ], being predominantly sexually transmitted, but is rare in Hong Kong, where it is largely confined to persons who inject drugs [
         <a href="#rid41">
          41
         </a>
         ]. In one report from Shanghai, that evaluated 225 serum samples from persons who were HBsAg-positive, anti-HDV was detected in 4.9 percent; however, they only tested hospitalized patients with elevated transaminase levels [
         <a href="#rid42">
          42
         </a>
         ]. A more recent study of 4103 HBsAg-positive sera from China found that prevalence of anti-HDV was limited to geographic hot spots in Mongolia, Xinjiang and high-risk persons who inject drugs and was not detected in any of 2364 HBsAg-positive persons in other areas [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Western countries
         </strong>
         – HDV infection is uncommon in Western countries and predominantly confined to high-risk groups, as described above [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Risk factors for disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         It should be noted that much of the data describing the epidemiology of HDV are based upon studies conducted more than 20 years ago, and updated information is not available in many countries.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to its dependence upon hepatitis B virus (HBV), HDV infection always occurs in association with HBV infection. The presentation depends in part upon whether the patient has acute infection (eg, HBV/HDV coinfection or acute HDV superinfection) or chronic HDV. In patients with chronic HDV, clinical manifestations can range from the asymptomatic carrier state to acute liver failure. (See
         <a class="local">
          'Virology'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         This section will review the clinical and laboratory findings associated with the different types of HDV infection (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ). The approach to diagnosing HDV is discussed below. (See
         <a class="local">
          'Diagnosis of HDV infection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3104517529">
         <span class="h2">
          Acute HBV/HDV coinfection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute HBV and acute HDV coinfection can occur in individuals susceptible to HBV infection (ie, hepatitis B surface antibody [anti-HBs]-negative). Clinically, this entity is indistinguishable from classical acute HBV infection and is usually transient and self-limited. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management", section on 'Acute infection'
         </a>
         .)
        </p>
        <p>
         Most patients with acute HBV/HDV infection recover from both HBV and HDV infection, but acute HBV/HDV infection is associated with a higher risk of acute liver failure than acute HBV monoinfection. The rate of progression to chronic HDV infection is similar to that observed for HBV since the persistence of HDV infection is dependent upon persistence of HBV infection [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2948341436">
         <span class="h2">
          Acute HDV superinfection
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDV superinfection in a patient with chronic HBV may present as a severe acute hepatitis in a previously unrecognized HBV carrier or as an exacerbation of pre-existing chronic hepatitis B. Progression to chronic HDV infection occurs in almost all patients [
         <a href="#rid44">
          44
         </a>
         ]; however, HBV replication is usually suppressed by HDV. Clinically, the presentation is often indistinguishable from those with acute HBV/HDV infection, but serologic testing may be able to separate the two entities (
         <a class="graphic graphic_figure graphicRef60216" href="/z/d/graphic/60216.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H123046775">
         <span class="h2">
          Chronic HDV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once chronic HDV infection is established, it usually exacerbates the pre-existing liver disease due to HBV. In general, chronic HDV infection is associated with more rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cirrhosis
         </strong>
         – In patients with chronic HDV, the initial progression towards cirrhosis tends to be rapid [
         <a href="#rid46">
          46,47
         </a>
         ] and is generally faster than among patients with HBV monoinfection [
         <a href="#rid48">
          48
         </a>
         ]. Progression from compensated to decompensated cirrhosis is less accelerated but still more rapid than that of HBV monoinfection. This was illustrated in a report from Italy in which the estimated 5- and 10-year probability of survival (free of liver transplantation) in patients who had already developed clinically overt cirrhosis was 49 and 40 percent, respectively [
         <a href="#rid48">
          48
         </a>
         ]. A more detailed discussion of the clinical manifestations of cirrhosis are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatocellular carcinoma
         </strong>
         – There also appears to be an increased risk of hepatocellular carcinoma in patients with chronic HDV. In a meta-analysis that included 93 observational studies, the pooled odds ratio of hepatocellular carcinoma in persons with HBV/HDV coinfection compared to HBV monoinfection was 2.77 (95% CI 1.79-4.28) [
         <a href="#rid49">
          49
         </a>
         ]. This association was seen even after adjusting for a higher prevalence of cirrhosis in those with HBV/HDV coinfection compared with HBV monoinfection; the association was particularly strong in prospective cohort studies.
        </p>
        <p>
        </p>
        <p>
         However, the clinical course of chronic HDV can vary, and in some patients HDV-associated chronic liver disease may run an indolent course [
         <a href="#rid49">
          49
         </a>
         ]. The clinical course is influenced by several factors, such as persistent HDV replication and HDV genotype. In a study of 299 patients with hepatitis D infection who were followed for up to 28 years, persistent HDV replication was associated with annual rates of development of cirrhosis and hepatocellular carcinoma of 4 and 2.8 percent, respectively [
         <a href="#rid50">
          50
         </a>
         ]. In this study, the only predictor of liver-related mortality was persistent HDV replication. The importance of genotypes is discussed below. (See
         <a class="local">
          'Importance of HDV genotypes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H887226830">
         <span class="h2">
          Importance of HDV genotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies have demonstrated that clinical outcomes may be related to the different HDV genotypes [
         <a href="#rid19">
          19,51,52
         </a>
         ], which seem to cluster in distinct geographical areas. However, superinfection, or mixed infection with different genotypes, can occur, particularly in patients who are at high risk for multiple exposures. In such patients, a single genotype usually predominates, with the minor genotype representing only approximately 10 percent of the total viral population [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype 1
         </strong>
         – In the Western world, where the predominant genotype is genotype 1, the clinical presentation can vary [
         <a href="#rid52">
          52
         </a>
         ]. As an example, patients with genotype 1 infection with acute hepatitis D infection have an increased risk of acute liver failure when compared with those with acute hepatitis B [
         <a href="#rid54">
          54
         </a>
         ]. In addition, once chronic HDV infection is established, it usually exacerbates the preexisting liver disease due to HBV [
         <a href="#rid44">
          44
         </a>
         ], and progression towards cirrhosis may be rapid [
         <a href="#rid46">
          46,47
         </a>
         ]. However, HDV-associated chronic liver disease may also run an indolent course [
         <a href="#rid55">
          55
         </a>
         ], and asymptomatic HDV carriers have been found in some geographical areas [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="local">
          'Geographic distribution'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many patients who are referred for evaluation of HDV were infected years ago; in such persons, HDV-related disease rapidly progressed to cirrhosis, but then subsequent disease progression was slow. This was illustrated in a report from Italy in which the estimated 5- and 10-year probability of survival free of liver transplantation in patients who had already developed clinically overt cirrhosis was 49 and 40 percent, respectively [
         <a href="#rid48">
          48
         </a>
         ]. However, patients with active HBV and HDV replication are more likely to develop liver decompensation [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether superimposed HDV infection accelerates the development of hepatocellular carcinoma in patients with hepatitis B surface antigen (HBsAg)-positive cirrhosis is controversial. However, a retrospective study involving 200 patients with compensated HBV-related cirrhosis, of whom 20 percent were HDV antibody (anti-HDV) positive, found that HDV infection increased the risk of hepatocellular carcinoma threefold and mortality twofold [
         <a href="#rid57">
          57
         </a>
         ]. After adjustment for clinical and serological differences at baseline, the estimated five-year risk for developing hepatocellular carcinoma was 13, 4, and 2 percent for anti-HDV-positive/hepatitis B e antigen (HBeAg)-negative, anti-HDV-negative/HBeAg-negative, and anti-HDV-negative/HBeAg-positive patients, respectively. The corresponding figures for hepatic decompensation were 18, 8, and 14 percent, respectively. In addition, a recent meta-analysis found that patients with superimposed HDV infection had a higher risk of hepatocellular carcinoma compared to those with HBV monoinfection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype 2
         </strong>
         – In the Far East, where the predominant genotype is genotype 2, the risk of acute liver failure and rapidly progressive liver disease is low compared to other HDV genotypes [
         <a href="#rid51">
          51,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype 3
         </strong>
         – Severe outbreaks of acute hepatitis D with a high incidence of acute liver failure have been reported in the Yukpa Indians of Venezuela [
         <a href="#rid59">
          59
         </a>
         ]; the Sierra Nevada de Santa Marta in Colombia [
         <a href="#rid60">
          60
         </a>
         ]; and some remote areas of the Brazilian [
         <a href="#rid61">
          61
         </a>
         ], Peruvian [
         <a href="#rid19">
          19
         </a>
         ], and Amazon basin. Viral factors have been postulated to be related to the fulminant course in these outbreaks, as HDV isolates from Colombia and Peru belong to a distinct viral genotype denoted genotype 3 [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other genotypes
         </strong>
         – At least five additional HDV genotypes have been described [
         <a href="#rid2">
          2,62
         </a>
         ]. Sequences previously assigned to genotype 2b are now classified as genotype 4, and African sequences seem to cluster into four additional genotypes, named from 5 to 8. These new genotypes are less well characterized as to their disease features compared with genotypes 1 to 3.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3368852311">
         <span class="h1">
          DIAGNOSIS OF HDV INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the dependence of HDV on hepatitis B virus (HBV), the presence of hepatitis B surface antigen (HBsAg) is necessary for the diagnosis of HDV infection. The additional presence of immunoglobulin (Ig)M antibody to hepatitis B core antigen (IgM anti-HBc) is necessary for the diagnosis of acute HBV/HDV coinfection (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3059188824">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic approach depends upon the clinical scenario.
        </p>
        <p class="headingAnchor" id="H2479181818">
         <span class="h3">
          Acute HBV and risk factors for HDV
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with acute HBV infection, testing for HDV coinfection should be performed in those who present with unusually severe or protracted hepatitis and those who have risk factors for HDV. (See
         <a class="local">
          'Risk factors for disease'
         </a>
         above.)
        </p>
        <p>
         Patients being evaluated for acute HBV/HDV coinfection should be tested for HBsAg, IgM anti-HBc, serum HDV RNA, and HDV antibody (anti-HDV).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with acute HBV are positive for HBsAg and have high titers of IgM anti-HBc. (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults", section on 'Acute hepatitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those with HDV coinfection, serum HDV RNA is usually detectable at presentation; by contrast, anti-HDV is often negative at presentation. If HDV RNA testing is not available, repeated testing for anti-HDV (total or IgM) should be performed to document anti-HDV seroconversion.
        </p>
        <p>
        </p>
        <p>
         Markers of HBV replication may precede or follow those of HDV. In addition, occasional patients have already seroconverted to hepatitis B surface antibody (anti-HBs) if they present during the second phase of biphasic hepatitis. These patients should still be positive for high-titer IgM anti-HBc (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H476884386">
         <span class="h3">
          Persons with chronic HBV and hepatitis flare
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDV superinfection should be evaluated in patients with chronic HBV who have acute hepatitis of unclear etiology. Patients should be tested for serum HDV RNA and anti-HDV.
        </p>
        <p>
         In persons with previously unrecognized chronic HBV, it can be difficult to determine if the person has HDV superinfection versus HDV coinfection; however, it is important to make this distinction because of the differences in prognosis (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ). When evaluating the patient, clinicians should be aware that:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HBsAg is present in both situations, but IgM anti-HBc should be negative in acute HDV superinfection (
         <a class="graphic graphic_figure graphicRef54793" href="/z/d/graphic/54793.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDV superinfection may cause transient suppression of HBV replication, resulting in very low and, rarely, undetectable levels of HBsAg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As in patients with acute HBV/HDV coinfection, patients with acute HDV superinfection usually have detectable HDV RNA in serum at the time of presentation. However, in contrast to acute coinfection, acute HDV superinfection is characterized by persistent detection of HDV RNA in serum and rapidly increasing titers of anti-HDV (total and IgM).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H433174650">
         <span class="h3">
          Persons with chronic HBV without hepatitis flare
         </span>
         <span class="headingEndMark">
          —
         </span>
         We test all patient with chronic HBV for HDV. Screening is particularly important for persons with risk factors for HDV. In a study from Spain, routine testing for anti-HDV in HBsAg-positive persons increased the number of anti-HDV-positive persons who were identified by a factor of five [
         <a href="#rid63">
          63
         </a>
         ]. Risk factors for HDV are described above. (See
         <a class="local">
          'Risk factors for disease'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial testing should be performed by testing for total anti-HDV antibody. (See
         <a class="local">
          'Detection of anti-HDV antibody'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of HDV infection should be confirmed by testing for serum HDV RNA. (See
         <a class="local">
          'Serum HDV RNA'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Patients with chronic HDV/HBV may also have certain characteristic findings on HBV testing. As an example, serum HBV DNA is usually present at low levels but may be undetectable. In addition, patients are often hepatitis B e antigen (HbeAg) negative and hepatitis B e antibody (anti-Hbe) positive. (See
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history", section on 'Phases of chronic HBV infection'
         </a>
         .)
        </p>
        <p>
         Identifying persons with chronic HDV/HBV is important since patients with coinfection may have more severe liver disease, and the presence of HDV can impact treatment decisions. In addition, the information can be used for counseling purposes so patients without HDV infection can reduce behaviors that might put them at risk for HDV superinfection. (See
         <a class="local">
          'Risk factors for disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3664.html" rel="external">
          "Treatment and prevention of hepatitis D virus infection"
         </a>
         .)
        </p>
        <p>
         Our approach to screening is consistent with European and Asian-Pacific guidelines, which recommend that persons with chronic HBV be evaluated for other causes of chronic liver disease, including HDV [
         <a href="#rid64">
          64,65
         </a>
         ]. However, other guidelines differ. As an example, United States guidelines recommend testing only for HbsAg-positive persons at high risk of HDV infection since there are no US Food and Drug Administration (FDA) approved HDV diagnostic tests, the reliability of tests in reference laboratories is variable, and the estimated prevalence of HDV infection ranges from very low to modest [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H358088417">
         <span class="h2">
          Diagnostic tests
         </span>
        </p>
        <p class="headingAnchor" id="H855313153">
         <span class="h3">
          Serum HDV RNA
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDV RNA can be detected in serum by reverse transcriptase-polymerase chain reaction (RT-PCR)-based assays (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         RT-PCR assays are very sensitive and may detect viral loads as low as 10 genomes per mL [
         <a href="#rid58">
          58,67-70
         </a>
         ]. However, the extensive sequence heterogeneity of different HDV isolates makes it difficult to choose suitable primers for the amplification of HDV RNA since only a few conserved regions exist in the HDV genome. In addition, the secondary and tertiary structure of the HDV RNA may hamper efficient amplification, even of highly conserved regions [
         <a href="#rid70">
          70
         </a>
         ]. The best efficiency is obtained by amplifying the C-terminal half of the HDV antigen (HDAg)-encoding region [
         <a href="#rid70">
          70
         </a>
         ]. Although automated assays are commercially available to allow quantification of HDV RNA in the serum of patients with HDV infection before and during treatment [
         <a href="#rid71">
          71,72
         </a>
         ], none of them have been approved for clinical use by the FDA, and performance of these assays is variable. Furthermore, it appears that differences in sample extracting and processing procedures may also influence accuracy of HDV RNA testing.
        </p>
        <p>
         HDV genotyping can be performed by direct sequencing [
         <a href="#rid19">
          19,51,52,73
         </a>
         ], but this test is not routinely recommended since the clinical relevance of HDV genotyping is uncertain. Furthermore, the phylogenetic classification of the various HDV genotypes is in debate [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         Sequence analysis of HDV RNA can also be used to detect common sources of infection, such as after intrafamilial or perinatal transmission [
         <a href="#rid74">
          74,75
         </a>
         ]. However, it is unclear if HDV RNA levels in the blood can be used as a prognostic factor to determine disease progression [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3433919379">
         <span class="h3">
          Detection of anti-HDV antibody
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total (IgM and IgG) anti-HDV antibodies can be detected by enzyme immunoassays (EIAs) or radioimmunoassays (RIAs) (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total anti-HDV antibody usually appears after four weeks of acute infection in acute hepatitis D (
         <a class="graphic graphic_figure graphicRef60216" href="/z/d/graphic/60216.html" rel="external">
          figure 2
         </a>
         ). As a result, its clinical value is limited unless repeated testing is performed [
         <a href="#rid76">
          76,77
         </a>
         ]. A well-documented anti-HDV seroconversion may be the only way to diagnose acute HDV infection in the absence of other markers of HDV infection. However, limited data suggest anti-HDV is short-lived in patients who do not develop chronic HBV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-titer anti-HDV of the IgG class is present in chronic HDV infection. It correlates well with ongoing HDV replication and may help in differentiating current from past HDV infection [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-HDV of the IgM class can be detected by EIAs or RIAs, but these assays are not available for clinical use in the United States [
         <a href="#rid79">
          79
         </a>
         ]. IgM anti-HDV is transient and delayed if the course of acute hepatitis D is self-limited, but it may be the only serum marker of acute HDV infection [
         <a href="#rid76">
          76
         </a>
         ]. In patients who progress to chronic HDV infection, which is usually the case in those with HDV superinfection, IgM anti-HDV is brisk and long-lasting. It should be remembered, however, that differentiating between HBV/HDV coinfection and HDV superinfection in an HBV carrier relies mainly on the detection of high-titer IgM anti-HBc in patients with coinfection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgM anti-HDV is present in high titers during chronic HDV infection, and the titers correlate with the level of HDV replication and severity of liver disease [
         <a href="#rid79">
          79
         </a>
         ], although HDV replication is best assessed by quantifying HDV RNA in serum. IgM anti-HDV gradually disappears from serum in patients who have persistent remission after interferon therapy and following liver transplantation [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1241523169">
         <span class="h3">
          Detection of serum HDAg
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum HDV antigen (HDAg) can be detected by EIA or RIA. However, these assays are rarely used and are not approved for clinical diagnosis in the United States.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In acute HDV infection, serum HDAg appears early, but its detection by EIA is short-lived and may require repeated testing (
         <a class="graphic graphic_figure graphicRef60216" href="/z/d/graphic/60216.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid76">
          76,77,81,82
         </a>
         ], except in immunocompromised individuals [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In chronic HDV infection, anti-HDV is present in high titers, but HDAg cannot be detected by EIA since it is complexed with anti-HDV. In this setting, serum HDAg is best detected by immunoblot assay [
         <a href="#rid4">
          4
         </a>
         ], which is more sensitive [
         <a href="#rid84">
          84
         </a>
         ]; however, this assay is technically difficult and time- and labor-consuming.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2709898570">
         <span class="h3">
          Tissue markers of HDV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both HDAg and HDV RNA can be detected in liver tissues routinely processed for histopathologic evaluation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDAg can be detected by direct immunofluorescence or immunohistochemistry. Although initially proposed as the "gold" standard for diagnosis of current HDV infection [
         <a href="#rid85">
          85
         </a>
         ], as many as 50 percent of liver biopsy specimens from patients who have been infected for 10 or more years may be negative for HDAg, suggesting that the levels of HDV replication may decrease with time [
         <a href="#rid58">
          58,86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who are negative for HDAg, the diagnosis of current HDV infection has to rely on the detection of HDV RNA or high-titer anti-HDV antibodies in the serum. (See
         <a class="local">
          'Serum HDV RNA'
         </a>
         above and
         <a class="local">
          'Detection of anti-HDV antibody'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDV RNA can be detected by in-situ hybridization. However, the techniques involved are time-consuming and tedious; they are not recommended for clinical use [
         <a href="#rid87">
          87
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1065225955">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Virology
         </strong>
         – Individuals with hepatitis D are always dually infected with hepatitis D virus (HDV) and hepatitis B virus (HBV). Although HDV can replicate autonomously, the simultaneous presence of HBV is required for complete virion assembly and secretion. Due to mechanisms that are not well understood, HBV replication is suppressed in most HDV-infected individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevalence
         </strong>
         – The prevalence of HDV in patients with chronic HBV infection varies across studies. Historical data suggest that approximately 15 to 20 million of the 257 million HBV carriers worldwide may be infected with HDV. In more recent studies, the prevalence has varied ranging from 12 to 60 million infections globally. In the United States, the prevalence of HDV infection has ranged from 6 to 42 percent of persons with chronic HBV. (See
         <a class="local">
          'Prevalence of disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk factors for HDV
         </strong>
         – HDV is predominantly confined to groups with known risk factors for HDV (persons who inject drugs, individuals who have received multiple transfusions in the past, men who have sex with men who engage in unsafe sexual behaviors [eg, condomless sex with multiple partners], and persons who emigrated from countries with a high prevalence of HDV infection). (See
         <a class="local">
          'Risk factors for disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Geographic distribution
         </strong>
         – HDV is not distributed uniformly across the globe, and the geographic distribution of HDV infection does not parallel that of HBV. As an example, there is a high prevalence in the Mediterranean Basin, Mongolia, Moldova, and some countries in Western and Middle Africa, whereas other areas, including many Asian countries, are relatively spared despite the high prevalence of HBV infection. (See
         <a class="local">
          'Geographic distribution'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Patients with acute HDV may present with acute HBV/HDV coinfection or, in persons with pre-existing chronic HBV, acute HDV superinfection. Clinically, the presentation is often indistinguishable, but serologic testing may be able to separate the two entities (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Acute HBV/HDV coinfection'
         </a>
         above and
         <a class="local">
          'Acute HDV superinfection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with chronic HDV, infection ranges from the asymptomatic carrier state to acute liver failure. The clinical course is influenced by several factors, such as persistent HDV replication and HDV genotype. (See
         <a class="local">
          'Chronic HDV infection'
         </a>
         above and
         <a class="local">
          'Importance of HDV genotypes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic approach
         </strong>
         – The diagnostic approach depends upon the clinical scenario. Diagnostic tests for HDV typically include HDV antibody (anti-HDV) antibody and HDV RNA. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above and
         <a class="local">
          'Diagnostic tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Persons with acute HBV infection and risk factors for HDV
         </strong>
         – In patients with acute HBV infection, testing for HDV coinfection should be performed in those who have risk factors for HDV or those who present with unusually severe or protracted hepatitis. Patients being evaluated for acute HBV/HDV coinfection should be tested for hepatitis B surface antigen (HbsAg), (hepatitis B core antigen) anti-HBc total and anti-HBc IgM, hepatitis B surface antibody (anti-HBs),
         <em>
         </em>
         serum HDV RNA, and HDV antibody (anti-HDV). (See
         <a class="local">
          'Acute HBV and risk factors for HDV'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Persons with chronic HBV and hepatitis flare
         </strong>
         – HDV superinfection should be evaluated in patients with chronic HBV who have acute hepatitis of unclear etiology. Patients should be tested for serum HDV RNA and anti-HDV. In persons with previously unrecognized chronic HBV, it can be difficult to determine if the person has HDV superinfection versus HDV coinfection (
         <a class="graphic graphic_table graphicRef52583" href="/z/d/graphic/52583.html" rel="external">
          table 1
         </a>
         ); however, it is important to make this distinction because of the differences in prognosis. (See
         <a class="local">
          'Persons with chronic HBV and hepatitis flare'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Persons with chronic HBV without hepatitis flare
         </strong>
         – We perform routine screening for HDV in all patients with chronic HBV. Initial testing should assess for total anti-HDV antibody; if positive, HDV infection should be confirmed by testing for serum HDV RNA. Identifying persons with chronic HDV/HBV is important since patients with coinfection may have more severe liver disease, and the presence of HDV coinfection can impact treatment decisions. This information can also be used for counseling purposes so patients without HDV infection can reduce behaviors that might put them at risk for HDV superinfection. (See
         <a class="local">
          'Persons with chronic HBV without hepatitis flare'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bichko V, Netter HJ, Wu TT, Taylor J. Pathogenesis associated with replication of hepatitis delta virus. Infect Agents Dis 1994; 3:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol 2006; 307:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996; 380:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986; 58:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negro F, Korba BE, Forzani B, et al. Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks. J Virol 1989; 63:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo K, Hwang SB, Duncan R, et al. Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA. Virology 1998; 250:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaguchi Y, Filipovska J, Yano K, et al. Stimulation of RNA polymerase II elongation by hepatitis delta antigen. Science 2001; 293:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modahl LE, Macnaughton TB, Zhu N, et al. RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol 2000; 20:6030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang J, Nie X, Chang HE, et al. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol 2008; 82:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller ML, Gardener MR, Bogus ZC, et al. Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sjögren's Syndrome-Like Phenotype in Vivo. Pathog Immun 2016; 1:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chemin I, Pujol FH, Scholtès C, et al. Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. Hepatology 2021; 73:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappy P, Lucas Q, Kankarafou N, et al. No Evidence of Hepatitis C Virus (HCV)-Assisted Hepatitis D Virus Propagation in a Large Cohort of HCV-Positive Blood Donors. J Infect Dis 2021; 223:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pflüger LS, Schulze Zur Wiesch J, Polywka S, Lütgehetmann M. Hepatitis delta virus propagation enabled by hepatitis C virus-Scientifically intriguing, but is it relevant to clinical practice? J Viral Hepat 2021; 28:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roggenbach I, Chi X, Lempp FA, et al. HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection. Viruses 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Vargas J, Pereira de Oliveira R, Jacquet S, et al. HDV-Like Viruses. Viruses 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Vargas J, Amirache F, Boson B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat Commun 2019; 10:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casey JL, Brown TL, Colan EJ, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90:9016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JR, Hantz O, Vitvitski L, et al. Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic. J Gen Virol 1993; 74 ( Pt 9):1827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedile A, Rosina F, Saracco G, et al. Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 1991; 13:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res 1991; 364:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global Hepatitis Report, 2017. http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=21B5AA5BEFA9E117AF03AAEAB7EECAD1?sequence=1 (Accessed on July 09, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 2019; 68:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miao Z, Zhang S, Ou X, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis 2020; 221:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020; 73:523.
          </a>
         </li>
         <li class="breakAll">
          Global hepatitis report, 2017. World Health Organization. Available at: https://www.who.int/publications/i/item/9789241565455. (Accessed on December 12, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel EU, Thio CL, Boon D, et al. Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016. Clin Infect Dis 2019; 69:709.
          </a>
         </li>
         <li class="breakAll">
          Time for universal screening for hepatitis D - A study describing screening patterns, characteristics, and outcomes of hepatitis D virus infection. National AIDS Treatment Advocacy Project. Available at: https://www.natap.org/2022/HDV/110322_01.htm. (Accessed on January 02, 2023).
         </li>
         <li class="breakAll">
          Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States. National AIDS Treatment Advocacy Project. Available at: https://www.natap.org/2022/HDV/070122_03.htm. (Accessed on January 02, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology 2000; 32:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaeta GB, Stroffolini T, Smedile A, et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 2007; 46:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology 2007; 45:1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppola N, Alessio L, Onorato L, et al. HDV infection in immigrant populations. J Med Virol 2019; 91:2049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamal H, Aleman S, D-SOLVE Consortium. Natural history of untreated HDV patients: Always a progressive disease? Liver Int 2023; 43 Suppl 1:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisaturo M, Alessio L, Di Fraia A, et al. Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study. Infection 2022; 50:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroffolini T, Ciancio A, Furlan C, et al. Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium. J Viral Hepat 2020; 27:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol 2010; 16:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liaw YF, Chiu KW, Chu CM, et al. Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study. J Infect Dis 1990; 162:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lok AS, Wong A, Sporton S, et al. Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. J Hepatol 1992; 14:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu S, Zhang Y, Tang Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. BMC Infect Dis 2020; 20:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caredda F, d'Arminio Monforte A, Rossi E, et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res 1983; 143:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedile A, Dentico P, Zanetti A, et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol 2021; 74:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatology 1986; 6:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfaiate D, Clément S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020; 73:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JC, Choo KB, Chen CM, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niro GA, Smedile A, Andriulli A, et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JC, Huang IA, Huang YH, et al. Mixed genotypes infection with hepatitis D virus. J Med Virol 1999; 57:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonino F, Negro F, Baldi M, et al. The natural history of chronic delta hepatitis. Prog Clin Biol Res 1987; 234:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadziyannis SJ, Papaioannou C, Alexopoulou A. The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece. Prog Clin Biol Res 1991; 364:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadler SC, Alcala de Monzon M, Rivero D, et al. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992; 136:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popper H, Thung SN, Gerber MA, et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983; 3:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bensabath G, Hadler SC, Soares MC, et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987; 258:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gal F, Gault E, Ripault MP, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006; 12:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep 2022; 4:100547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for the Study of the Liver. Electronic address:
           <span class="__cf_email__" data-cfemail="d6b3b7a5bab9b0b0bfb5b396b3b7a5bab9b0b0bfb5b3f8b3a3">
            [email protected]
           </span>
           , European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zignego AL, Deny P, Feray C, et al. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes 1990; 4:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madejón A, Castillo I, Bartolomé J, et al. Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol 1990; 11:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cariani E, Ravaggi A, Puoti M, et al. Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. Hepatology 1992; 15:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinolfo L, Abate ML, Bertolo P, et al. Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay. Int J Clin Lab Res 1995; 25:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48:2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casey JL, Niro GA, Engle RE, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996; 174:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niro GA, Casey JL, Gravinese E, et al. Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol 1999; 30:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YH, Wu JC, Lu SN, et al. Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987; 1:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buti M, Esteban R, Jardí R, et al. Serological diagnosis of acute delta hepatitis. J Med Virol 1986; 18:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negro F, Bergmann KF, Baroudy BM, et al. Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. J Infect Dis 1988; 158:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedile A, Lavarini C, Crivelli O, et al. Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection. J Med Virol 1982; 9:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borghesio E, Rosina F, Smedile A, et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govindarajan S, Valinluck B, Peters L. Relapse of acute B viral hepatitis--role of delta agent. Gut 1986; 27:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shattock AG, Morgan BM. Sensitive enzyme immunoassay for the detection of delta antigen and anti-delta, using serum as the delta antigen source. J Med Virol 1984; 13:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grippon P, Ribiere O, Cadranel JF, et al. Long-term delta antigenaemia without appearance of delta antibody in two immunodeficient patients. Lancet 1987; 1:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buti M, Esteban R, Jardi R, et al. Chronic delta hepatitis: detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication. Hepatology 1989; 10:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Bisceglie AM, Negro F. Diagnosis of hepatitis delta virus infection. Hepatology 1989; 10:1014.
          </a>
         </li>
         <li class="breakAll">
          Bonino F, Negro F, Baldi M, et al. The natural history of chronic delta hepatitis. In: The hepatitis delta virus and its infection, Rizzetto M, Gerin JL, Purcell RH (Eds), Alan R Liss, New York 1987. p.145.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negro F, Rizzetto M. Diagnosis of hepatitis delta virus infection. J Hepatol 1995; 22:136.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3666 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7812659" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pathogenesis associated with replication of hepatitis delta virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16903225" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602246" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3701932" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2926865" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24361467" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25409679" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9770424" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11387440" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Stimulation of RNA polymerase II elongation by hepatitis delta antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10913185" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032511" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Transcription of hepatitis delta virus RNA by RNA polymerase II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27294212" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hepatitis Delta Virus Detected in Salivary Glands of Sjögren's Syndrome Patients and Recapitulates a Sjögren's Syndrome-Like Phenotype in Vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32628280" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804999" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : No Evidence of Hepatitis C Virus (HCV)-Assisted Hepatitis D Virus Propagation in a Large Cohort of HCV-Positive Blood Donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32852870" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hepatitis delta virus propagation enabled by hepatitis C virus-Scientifically intriguing, but is it relevant to clinical practice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34578380" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34201626" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : HDV-Like Viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31068585" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8415646" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A genotype of hepatitis D virus that occurs in northern South America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8376962" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1999312" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2020686" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Epidemiology of hepatitis delta virus: overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20051970" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20051970" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30228220" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31778167" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32335166" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32335166" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605508" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605508" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605508" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11003629" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chronic hepatitis D: a vanishing Disease? An Italian multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17894318" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hepatitis delta in Europe: vanishing or refreshing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17464980" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hepatitis D virus infection--not a vanishing disease in Europe!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31429940" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : HDV infection in immigrant populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36308026" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Natural history of untreated HDV patients: Always a progressive disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36222979" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32338810" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20128022" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hepatitis D: Scenario in the Asia-Pacific region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2121838" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1500697" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32746807" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6669581" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prospective study of epidemic delta infection in drug addicts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7286594" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Infection with the delta agent in chronic HBsAg carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33484770" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The changing context of hepatitis D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6340574" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3525368" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381923" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Changing pattern of chronic hepatitis D in Southern Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32151618" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208358" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564729" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9049226" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The predominance of hepatitis delta virus genotype I among chronically infected Italian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9890423" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mixed genotypes infection with hepatitis D virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127458" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Influence of delta infection on severity of hepatitis B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3628373" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The natural history of chronic delta hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2020721" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673308" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7875481" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1288280" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6629319" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Histologic studies of severe delta agent infection in Venezuelan Indians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3599343" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17073101" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Eighth major clade for hepatitis delta virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36052219" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28427875" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26563120" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405329" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2314396" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2290030" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1372582" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7787208" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20351206" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20346531" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896491" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10207796" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Intrafamilial transmission of hepatitis delta virus: molecular evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10063709" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2881041" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Serological response to the hepatitis delta virus in hepatitis D.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3944592" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Serological diagnosis of acute delta hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3392412" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6175733" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9500721" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3949233" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Relapse of acute B viral hepatitis--role of delta agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6363622" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Sensitive enzyme immunoassay for the detection of delta antigen and anti-delta, using serum as the delta antigen source.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2883365" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Long-term delta antigenaemia without appearance of delta antibody in two immunodeficient patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2583685" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Chronic delta hepatitis: detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2491738" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Diagnosis of hepatitis delta virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2491738" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Diagnosis of hepatitis delta virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7602066" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Diagnosis of hepatitis delta virus infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
